Status:
UNKNOWN
Treatment Youth With Obsessive-Compulsive Disorder
Lead Sponsor:
University of Ottawa
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
13-19 years
Phase:
PHASE4
Brief Summary
Although research suggests that patients with obsessive-compulsive disorder (OCD) exhibit specific deficits in their high cognitive processes, it is still unknown how these deficits relate to the clin...
Detailed Description
Rationale. Obsessive-compulsive disorder (OCD) often has a childhood onset, and is characterized by recurrent obsessions and compulsions that are perceived as irrational and cause significant interfer...
Eligibility Criteria
Inclusion
- Be 13 to 19 years old
- Have at least average intellectual ability
- Currently meet DSM-IV-TR criteria for OCD, upon completion of the Anxiety Disorder Interview Schedule for DSM-IV - Research and Lifetime Version for child and parent (ADIS- RLV)
- Receive a total score equal to or greater than 20 on the CY-BOCS at the screening visit have less than 25% decrease on the CY-BOCS total score between the screening and baseline visit
- If female of childbearing potential and sexually active in a heterosexual relationship, the subject must be using a reliable method of contraception, such as hormonal contraceptives
- Oral contraceptives must have been started at least 3 months prior to the start of the study
Exclusion
- Clinically significant and/or unstable medical condition, including cardiovascular, respiratory, hematological, neurological and endocrine diseases
- History of neurological disorder or head injury
- Current use of medication with central nervous system effects
- Substance abuse or dependence within 6 months prior to enrolment
- Contra-indication to the fMRI
- Color blindness
- A comorbid current DSM-IV Axis I diagnosis, except for tic disorders and another anxiety disorder, as long as the associated disorder is less disabling than the primary diagnosis of OCD, as can be assessed with the ADIS
- Patients who would require additional psychological or pharmacological treatment
- Significant suicide risk, based on clinical judgment and the relevant section of the ADIS
- Hypersensitivity to escitalopram
- Previous non-response to an adequate trial of escitalopram
- Any lifetime psychiatric disorder as assessed on the ADIS
- A lifetime diagnosis of schizophrenia in biological parents or siblings
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00708240
Start Date
January 1 2007
End Date
December 1 2010
Last Update
July 2 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Institute of Mental Health Research
Ottawa, Ontario, Canada, K1Z7K4